v3.19.1

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 8,761	$ 9,947	$ 27,384	$ 30,213
Cost of sales (exclusive of depreciation and amortization shown separately down below)	6,650	7,367	20,431	22,083
Gross profit	2,111	2,580	6,953	8,130
Operating expenses
Selling, general and administrative expenses	2,285	2,632	7,233	7,820
Non-cash stock compensation	1	11	(6)	26
Depreciation and amortization	231	249	713	769
Total operating expenses	2,517	2,892	7,940	8,615
Operating loss	(406)	(312)	(987)	(485)
Other income	47	0	135	0
Interest income	0	0	33	0
Interest expense	(118)	(115)	(339)	(317)
Loss on disposal of assets and investment impairment	0	0	0	(75)
Loss before provision for income tax	(477)	(427)	(1,158)	(877)
Income tax provision	(2,006)	(9)	(2,022)	(32)
Net loss	$ (2,483)	$ (436)	$ (3,180)	$ (909)
Basic and diluted net loss per share attributable to common stockholders	$ (0.11)	$ (0.02)	$ (0.14)	$ (0.04)
Weighted-average number of shares - Basic and diluted	23,097,914	22,476,821	23,087,347	22,450,017

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Dougherty's Pharmacy, Inc. 10-Q